Hyper IgM Syndrome

Definition and genetics

Definition: A group of disorders caused by defects in molecules required for immunoglobulin class switching, most commonly mutations in the CD40 ligand (CD40L) on T cells, resulting in impaired switching from IgM to IgG and IgA.

Inheritance patterns: Most cases are X‑linked (CD40L), affecting boys; autosomal recessive forms affecting both sexes result from defects in CD40, AID, UNG, or other genes.

Incidence and age at presentation

Incidence: X‑linked Hyper IgM is rare; exact incidence varies by population but is an uncommon primary immunodeficiency.

Typical onset: Most present in infancy or early childhood with recurrent or severe infections, including opportunistic infections such as Pneumocystis jirovecii.

Laboratory features

• Immunoglobulins: Low or absent IgG and IgA with normal or elevated IgM.
• Antibody function: Poor specific antibody responses to vaccines.
• Other: Neutropenia may be present in a subset of patients; confirmatory genetic testing depends on clinical suspicion and initial lab findings.

Gastrointestinal manifestations

GI disease is a major source of morbidity and may be infectious, inflammatory, or neoplastic over time.

• Chronic or recurrent diarrhea frequently due to enteric pathogens including Cryptosporidium parvum and Giardia.
• Cryptosporidial cholangitis that can progress to sclerosing cholangitis and cirrhosis.
• Large oral and rectal ulcerations and mucosal ulcerative disease.
• Hepatosplenomegaly common with chronic infections or immune dysregulation.
• Intestinal lymphoid hyperplasia observed on endoscopy or histology.
• Long‑term risks: Cholangiocarcinoma and hepatocellular carcinoma reported in survivors with chronic biliary disease.

Extraintestinal risks

• Malignancy risk: Increased risk of lymphoma and certain other cancers in some forms of Hyper IgM.
• Other: Autoimmune manifestations and chronic inflammatory complications may occur.

Management

• Immunoglobulin replacement therapy: Routine Ig replacement reduces bacterial infections and morbidity.
• Antimicrobials and prophylaxis: Trimethoprim‑sulfamethoxazole for Pneumocystis prophylaxis; pathogen‑directed therapy for enteric infections; consider prolonged treatment for chronic protozoal or viral infections.
• Definitive therapy: Hematopoietic stem cell transplantation (HSCT) is curative for appropriate candidates and should be considered early for X‑linked CD40L deficiency, especially with severe or progressive disease.
• Supportive care: Monitor and manage liver/biliary disease, nutritional status, and complications such as sclerosing cholangitis or malignancy with multidisciplinary teams.

Clinical pearls